CU20210023A7 - Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 - Google Patents

Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4

Info

Publication number
CU20210023A7
CU20210023A7 CU2021000023A CU20210023A CU20210023A7 CU 20210023 A7 CU20210023 A7 CU 20210023A7 CU 2021000023 A CU2021000023 A CU 2021000023A CU 20210023 A CU20210023 A CU 20210023A CU 20210023 A7 CU20210023 A7 CU 20210023A7
Authority
CU
Cuba
Prior art keywords
phosphodiesterase
oxaborolan
pyridinyl
inhibitors
substitute phenyl
Prior art date
Application number
CU2021000023A
Other languages
English (en)
Inventor
Tsutomu Akama
David Clive Blakemore
Robert Toms Jacobs
Peter Jones
David Christopher Limburg
Martins Sunday Oderinde
Matthew Alexander Perry
Jacob John Plattner
Joseph Walter Strohbach
Rubben Federico Torella
Thean Yeow Yeoh
Yasheen Zhou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20210023A7 publication Critical patent/CU20210023A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

<p>La presente invención se refiere a compuestos inhibidores de la fosfodiesterasa 4 de Fórmula (IA) o Fórmula (IB).</p> <p>ESPACIO PARA FÓRMULA</p> <p>o una sal farmaceúticamente aceptable de los mismos, en los que R1, R2, R3, R4, R5, R6, R7,R9,R10, A1, A2 y p son como se define en el presente documento.</p>
CU2021000023A 2018-10-05 2019-10-01 Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 CU20210023A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741868P 2018-10-05 2018-10-05
US201962889599P 2019-08-21 2019-08-21
PCT/IB2019/058355 WO2020070651A1 (en) 2018-10-05 2019-10-01 Boron containing pde4 inhibitors

Publications (1)

Publication Number Publication Date
CU20210023A7 true CU20210023A7 (es) 2021-10-12

Family

ID=68136492

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000023A CU20210023A7 (es) 2018-10-05 2019-10-01 Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4

Country Status (28)

Country Link
US (3) US10946031B2 (es)
EP (1) EP3861001B1 (es)
JP (1) JP7048823B2 (es)
KR (1) KR102576125B1 (es)
CN (1) CN113166177A (es)
AU (1) AU2019351960B2 (es)
BR (1) BR112021005870B1 (es)
CA (1) CA3114702C (es)
CL (1) CL2021000843A1 (es)
CO (1) CO2021003928A2 (es)
CR (1) CR20210163A (es)
CU (1) CU20210023A7 (es)
DK (1) DK3861001T3 (es)
DO (1) DOP2021000055A (es)
EC (1) ECSP21023404A (es)
FI (1) FI3861001T3 (es)
GE (1) GEP20227442B (es)
IL (1) IL282083A (es)
MA (1) MA53808A (es)
MX (1) MX2021003871A (es)
NI (1) NI202100020A (es)
PE (1) PE20211546A1 (es)
PH (1) PH12021550743A1 (es)
SG (1) SG11202102674RA (es)
TW (1) TWI764052B (es)
UY (1) UY38400A (es)
WO (1) WO2020070651A1 (es)
ZA (1) ZA202101822B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002086A (es) 2020-08-20 2023-03-15 Pfizer Formulaciones topicas estables de 1(r)-4-(5-(4-metoxi-3-propoxifen il)piridin-3-il)-1,2-oxaborolan-2-ol.
US20230340530A1 (en) 2020-08-31 2023-10-26 Pfizer Inc. Methods of Protecting RNA
WO2022135550A1 (zh) 2020-12-25 2022-06-30 瑞石生物医药有限公司 一种硼酸酯衍生物及其用途
WO2023246854A1 (zh) * 2022-06-24 2023-12-28 瑞石生物医药有限公司 一种硼酸酯衍生物的结晶、其制备方法及用途
WO2023246858A1 (zh) * 2022-06-24 2023-12-28 瑞石生物医药有限公司 一种硼酸酯衍生物的可药用盐、其结晶形式及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
KR101337068B1 (ko) * 2005-02-16 2013-12-06 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
JP5745279B2 (ja) * 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
US8039450B2 (en) * 2008-03-06 2011-10-18 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
TW201221131A (en) * 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
EP2763538A2 (en) 2011-10-07 2014-08-13 Syngenta Participations AG Method for protecting useful plants or plant propagation material
NZ705881A (en) * 2012-10-25 2018-04-27 Tetra Discovery Partners Llc Heteroaryl inhibitors of pde4
EP2752196A1 (en) * 2013-01-03 2014-07-09 Université Bordeaux Segalen Selective nox-1 inhibitor peptides and uses thereof
CA2899317A1 (en) 2013-01-30 2014-08-07 Dow Agrosciences Llc Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts
WO2014147009A1 (en) * 2013-03-18 2014-09-25 Syngenta Participations Ag Novel microbiocides
AU2014202928B1 (en) 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
MX2020006613A (es) * 2017-12-22 2020-11-13 Ravenna Pharmaceuticals Inc Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.

Also Published As

Publication number Publication date
MA53808A (fr) 2022-01-12
ECSP21023404A (es) 2021-05-31
GEP20227442B (en) 2022-11-25
DK3861001T3 (da) 2024-01-15
PE20211546A1 (es) 2021-08-16
CL2021000843A1 (es) 2021-09-10
JP7048823B2 (ja) 2022-04-05
CN113166177A (zh) 2021-07-23
PH12021550743A1 (en) 2021-10-11
US11559538B2 (en) 2023-01-24
UY38400A (es) 2020-04-30
AU2019351960A1 (en) 2021-04-29
BR112021005870B1 (pt) 2024-01-09
US20200108083A1 (en) 2020-04-09
CO2021003928A2 (es) 2021-04-19
BR112021005870A2 (pt) 2021-07-27
US20210069219A1 (en) 2021-03-11
CA3114702A1 (en) 2020-04-09
SG11202102674RA (en) 2021-04-29
EP3861001A1 (en) 2021-08-11
DOP2021000055A (es) 2021-05-16
MX2021003871A (es) 2021-05-27
IL282083A (en) 2021-05-31
CA3114702C (en) 2023-08-08
TW202027755A (zh) 2020-08-01
AU2019351960B2 (en) 2022-07-28
KR20210068532A (ko) 2021-06-09
TWI764052B (zh) 2022-05-11
CR20210163A (es) 2021-06-24
ZA202101822B (en) 2022-08-31
JP2021534222A (ja) 2021-12-09
KR102576125B1 (ko) 2023-09-08
US10946031B2 (en) 2021-03-16
FI3861001T3 (fi) 2024-01-03
US20230148402A1 (en) 2023-05-11
WO2020070651A1 (en) 2020-04-09
EP3861001B1 (en) 2023-12-13
NI202100020A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
UY38057A (es) Inhibidores de sarcómero cardíaco
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
CR20140413A (es) Inhibidores de serina/treonina cinasa
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
UA117151C2 (uk) N-ациліміногетероциклічні сполуки
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR086482A1 (es) Inhibidores de aldosterona sintasa
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
CL2021001461A1 (es) Moduladores de trex1
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
CL2020002550A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos.
CU20210016A7 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
CU20110101A7 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
NI201100035A (es) Agentes antifúngicos.